Article
Endocrinology & Metabolism
Jinhua Xu, Jingjing Li, Guofeng Wu, Yajun Ren, Xue Wang, Qianyun Zhang
Summary: The study evaluated the effects of pemetrexed combined with cisplatin on the immune system of NSCLC patients. The results showed that patients treated with pemetrexed plus cisplatin had higher levels of interferon-γ and tumor necrosis factor-alpha, and lower levels of CD4+ T cells and tumor markers compared to those treated with docetaxel plus cisplatin.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2023)
Article
Oncology
Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, YongQian Shu, Jianhua Shi, Yi Hu, QiMing Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, LiPing Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, XiaoRong Dong, Faguang Jin, Hongjun Gao, Guangyu An, Cuimin Ding, Xiaodong Jiang, Jianping Xiong, Xiangdong Zhou, Sheng Hu, Ping Lu, Anwen Liu, Shuliang Guo, Jianjin Huang, Chengchu Zhu, Jian Zhao, Beili Gao, Yinglan Chen, Chengping Hu, Jian Zhang, Hongmei Zhang, Hui Zhao, Yanfei Tai, Xinjing Ma, Wei Shi, CameL Study Grp
Summary: The addition of camrelizumab to first-line chemotherapy significantly improves the progression-free survival of patients with advanced nonsquamous NSCLC. It provides long-term survival benefit with manageable toxicity and durable response. These results support the combination of camrelizumab and chemotherapy as a first-line treatment for advanced nonsquamous NSCLC.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Laurence Booth, Andrew Poklepovic, John F. Hancock, Paul Dent
Summary: The combination of neratinib and pemetrexed synergistically kills NSCLC cells, but no early resistance mechanisms were observed. Further research is needed to understand how NSCLC cells develop resistance to neratinib and pemetrexed.
Article
Oncology
T. C. Lam, K. C. Tsang, H. C. Choi, V. H. Lee, K. O. Lam, C. L. Chiang, T. H. So, W. W. Chan, S. F. Nyaw, F. Lim, J. O. Lau, J. Chik, F. M. Kong, A. W. Lee
Summary: This study confirmed the promising efficacy of the combination of atezolizumab, bevacizumab, pemetrexed, and carboplatin in EGFR mutated lung cancer after TKI failure. Treatment-related adverse events were common, but quality of life measures did not change significantly.
Article
Oncology
Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih-Hsin Yang, Steven F. Powell, Ryan D. Gentzler, Renato G. Martins, James P. Stevenson, Mehmet Altan, Shadia I. Jalal, Amit Panwalkar, Matthew Gubens, Lecia V. Sequist, Sanatan Saraf, Bin Zhao, Bilal Piperdi, Corey J. Langer
Summary: First-line pembrolizumab plus pemetrexed-carboplatin showed continued improved response and survival compared to chemotherapy alone in advanced nonsquamous NSCLC, with durable clinical benefit in patients who completed 2 years of therapy. No new safety signals were observed with longer follow-up.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Laurence Booth, Cameron West, Robert P. Moore, Daniel Von Hoff, Paul Dent
Summary: Our study reveals that the combination of GZ17-6.02 and pemetrexed can effectively kill osimertinib-resistant NSCLC cells.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Giorgio Cannone, Giovanni Maria Comacchio, Giulia Pasello, Eleonora Faccioli, Marco Schiavon, Andrea Dell'Amore, Marco Mammana, Federico Rea
Summary: The introduction of immunotherapy and targeted therapy has led to changes in thoracic surgical practice for non-small cell lung cancer (NSCLC), with surgeons paying more attention to the genomic and molecular features of the disease and the potential for multimodality treatments.
Article
Oncology
Mark G. Faber, Chong Wang, Sruthi Kommi Reddy, Alison Meagher, Amy Early, Hongbin Chen, Grace K. Dy
Summary: This study compared treatment outcomes between patients receiving maintenance pemetrexed therapy on a standard schedule and an alternate schedule. The results showed that patients on the alternate schedule had a longer time on maintenance treatment and trended towards better overall survival.
Article
Multidisciplinary Sciences
Vamsidhar Velcheti, Xiaohan Hu, Bilal Piperdi, Thomas Burke
Summary: The study demonstrated the effectiveness of first-line pembrolizumab-combination therapy for metastatic nonsquamous NSCLC patients treated at US oncology practices, showing promising clinical outcomes.
SCIENTIFIC REPORTS
(2021)
Article
Biology
Ling Zhou, Wenchao Zhang, Yi Xiang, Zijun Qian, Jianping Zhou, Lei Ni, Yun Feng, Beili Gao
Summary: This study investigated the combined effect of apatinib and chemotherapeutic agents in treating non-small-cell lung cancer. The results suggest that the combination of apatinib and pemetrexed may be a promising alternative therapy for lung cancer patients.
OPEN LIFE SCIENCES
(2023)
Article
Oncology
Zhenzhou Yang, Yan Zhang, Rongqing Li, Abulimiti Yisikandaer, Biyong Ren, Jianguo Sun, Jianjun Li, Long Chen, Ren Zhao, Juying Zhang, Xuefeng Xia, Zhongxing Liao, David P. Carbone
Summary: The study evaluated the efficacy of concurrent erlotinib with whole-brain radiotherapy in NSCLC patients with brain metastases. The findings indicated that the combination therapy did not significantly improve intracranial progression-free survival and did not lead to significant cognitive function impairment.
Article
Oncology
Fabian J. J. Bolte, Sloane McTavish, Nathan Wakefield, Lindsey Shantzer, Caroline Hubbard, Arun Krishnaraj, Wendy Novicoff, Ryan D. D. Gentzler, Richard D. D. Hall
Summary: This study investigated the association of sarcopenia with overall survival in patients with advanced non-small cell lung cancer undergoing concurrent immune checkpoint inhibitor and chemotherapy treatment. The results showed that sarcopenia was independently associated with poor overall survival, along with other factors such as ECOG score, prognostic nutritional index, and immune-related adverse events.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Hui Liu, Chunlei Guo, Yuhong Shang, Lin Zeng, Haixue Jia, Zhongyan Wang
Summary: Supramolecular nanoparticles consisting of peptides and drugs, particularly RGD-conjugated molecular nanoparticles containing the anticancer drug PEM, show enhanced cytotoxic activity and antitumor efficacy compared to PEM alone. These nanoparticles have great potential for application in lung cancer therapy by promoting tumor apoptosis and decreasing mitochondrial energy metabolism.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Article
Engineering, Biomedical
Jian Xu, Wei Xu, Zhiqiang Wang, Yuequan Jiang
Summary: Lung cancer, a common cancer, can be treated with surgery, chemotherapy, and combined radiotherapy. This study developed a nanoplatform for the combined treatment of non-small cell lung cancer (NSCLC) using pemetrexed-loaded mesoporous polydopamine nanoparticles. The results showed that these nanoparticles had excellent photothermal conversion properties and could effectively inhibit the growth of NSCLC cells through a combination of therapy methods.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
(2023)
Article
Hematology
Ryan C. Lynch, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Brian Till, Vikram M. Raghunathan, Stefan Alig, Ash A. Alizadeh, Avanti Gulhane, Delphine L. Chen, Yolanda Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jacquelin Vandermeer, Ashley Gaston, Heather Rasmussen, Paul Martin, Edmond Marzbani, Jenna Voutsinas, Ajay K. Gopal
Summary: This study investigated the concurrent administration of pembrolizumab with chemotherapy in untreated classic Hodgkin lymphoma, showing promising safety and efficacy. Although some patients experienced adverse events, the overall response rate was 100% with a complete response rate of 90%.
Article
Oncology
R. Daniel Bonfil, Wei Chen, Semir Vranic, Anjum Sohail, Dongping Shi, Hyejeong Jang, Hyeong-Reh Kim, Marco Prunotto, Rafael Fridman
Summary: The research suggests that the membranous expression level of DDR1 in prostate cancer patients may serve as a potential biomarker for better determination of PCa aggressiveness.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Yutuan Wu, Jie Huang, Cristina Ivan, Yunjie Sun, Shaolin Ma, Lingegowda S. Mangala, Bryan M. Fellman, Diana L. Urbauer, Nicholas B. Jennings, Prahlad Ram, Robert L. Coleman, Wei Hu, Anil K. Sood
Summary: The study revealed that the MAPK pathway is activated in dasatinib-resistant uterine cancer cells, and EphrinA1-mediated MEK inhibition can overcome resistance. Dual targeting of EphA2 and MEK, along with chemotherapy, should be considered for future clinical development.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yu Wang, Ran Guo, Wei Hu, Jianfeng Zheng, Qingyan Wang, Jay Jiang, Krishna K. N. Kurpad, Norbert Kaula, Stuart Long, Ji Chen, Wolfgang Kainz
Summary: The study investigates the heating of abandoned AIMD leads with different proximal end treatments, finding that lead-tip heating is lower when terminated with metal compared to being insulated with plastic, which could result in up to 3.5 times higher temperature rise.
MAGNETIC RESONANCE IN MEDICINE
(2022)
Meeting Abstract
Oncology
Elizabeth Weisberg, Hadeel Assad, Lydia Choi-Kim, Tammy DeMeere, Hyejeong Jang, Wei Chen, Mary Ann Kosir
Article
Cardiac & Cardiovascular Systems
Arsalan Hamid, Markus S. Anker, John C. Ruckdeschel, Muhammad Shahzeb Khan, Arsal Tharwani, Adebamike A. Oshunbade, Rodney K. Kipchumba, Samuel C. Thigpen, Stefan D. Anker, Gregg C. Fonarow, Michael E. Hall, Javed Butler
Summary: The study found that patients with cardiovascular conditions or prevalent cardiovascular disease were significantly underrepresented in contemporary later-phase breast cancer trials, and cardiovascular safety was not routinely monitored in these trials.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Oncology
Ulka N. Vaishampayan, Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson, Brenda Dickow, Dana Schalk, Amy Schienschang, Sarah Whitaker, Amanda Polend, Joseph A. Fontana, Elisabeth I. Heath, Lawrence G. Lum
Summary: This study aimed to evaluate the safety and efficacy of the combination of HER2 bispecific antibody (HER2Bi)-armed activated T cells (HER2 BAT) and programmed death 1 inhibitor, pembrolizumab, in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The results showed that this combination therapy had good safety and efficacy in mCRPC patients, indicating the need for further investigation.
CLINICAL CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Allison Mitchell, Ling Wu, C. James Block, Mu Zhang, Justin Hackett, Douglas B. Craig, Wei Chen, Yongzhong Zhao, Bin Zhang, Yongjun Dang, Xiaohong Zhang, Shengping Zhang, Chuangui Wang, Heather Gibson, Lori A. Pile, Benjamin Kidder, Larry Matherly, Zhe Yang, Yali Dou, Guojun Wu
Summary: The study reveals that FOXQ1 recruits the MLL/KMT2 histone methyltransferase complex as a transcriptional coactivator to initiate EMT in breast cancer. Disruption of FOXQ1-RbBP5 interaction or pharmacologic targeting of KMT2/MLL recruitment inhibits FOXQ1-dependent gene expression, EMT, and in vivo tumor progression. Targeting the FOXQ1-MLL epigenetic axis could be a promising strategy against metastatic progression in triple-negative breast cancer.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Wei Chen, Liying Yan, Bo Long, Li Lin
Summary: In this study, we developed a prognostic model based on immune-related genes and lncRNAs for predicting the prognosis and response to immunotherapy in uveal melanoma patients. The model accurately predicted patient prognosis and response, and showed significant correlations with immune-related pathways and molecules. This model has valuable clinical applications in antitumor immunotherapy.
JOURNAL OF ONCOLOGY
(2022)
Article
Oncology
Federico Canzian, Cosmeri Rizzato, Angelika Stein, Lourdes Flores-Luna, Margarita Camorlinga-Ponce, Alfonso Mendez-Tenorio, Wei Chen, Elena Kasamatsu, Maria Mercedes Bravo, Javier Torres, Nubia Munoz, Ikuko Kato
Summary: Infection by Helicobacter pylori is causally linked to gastric cancer risk. The coevolution of Hp and humans shaped the risk of gastric cancer. Latin America is a high-risk region for gastric cancer and Hp has evolved uniquely there since European colonization. The study examines whether the phylogenetic origin of Hp contributes to gastric cancer risk in Latin America.
EUROPEAN JOURNAL OF CANCER PREVENTION
(2023)
Article
Biochemistry & Molecular Biology
Steven D. D. Hicks, Dongxiao Zhu, Rhea Sullivan, Nirupama Kannikeswaran, Kathleen Meert, Wei Chen, Srinivasan Suresh, Usha Sethuraman
Summary: Salivary miRNA levels are perturbed in children with severe COVID-19, with the majority of miRNAs being down regulated. Further studies are required to validate and determine the utility of salivary miRNAs as biomarkers of severe COVID-19.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Guoli Wang, Xin He, Huiqi Dai, Lingyi Lin, Wenmin Cao, Yao Fu, Wenli Diao, Meng Ding, Qing Zhang, Wei Chen, Hongqian Guo
Summary: Elevated expression of WDR4 in bladder cancer is associated with worse prognosis, as it promotes lymph node metastasis and proliferation of bladder cancer cells. WDR4 acts as an adaptor to bind DDX20 and Egr1, inhibiting Egr1-promoted transcriptional expression of ARRB2 and contributing to the progression of bladder cancer. WDR4 could be a potential therapeutic target for metastatic bladder cancer.
Article
Oncology
Joshua Kong, Sudeshna Bandyopadhyay, Wei Chen, Faisal Al-Mufarrej, Lydia Choi, Mary A. Kosir
Summary: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with a poor survival rate. Intraoperative frozen section analysis (FSA) can decrease the number of positive margins in IBC patients undergoing modified radical mastectomy (MRM), potentially reducing the need for re-operation, allowing immediate wound closure, and preventing delays in adjuvant radiation therapy.
Article
Biochemistry & Molecular Biology
Joshua R. Heyza, Elmira Ekinci, Jacob Lindquist, Wen Lei, Christopher Yunker, Vilvanathan Vinothkumar, Rachelle Rowbotham, Lisa Polin, Natalie G. Snider, Eric Van Buren, Donovan Watza, Jessica B. Back, Wei Chen, Hirva Mamdani, Ann G. Schwartz, John J. Turchi, Gerold Bepler, Steve M. Patrick
Summary: ERCC1/XPF is critical for repair of certain chemotherapeutic agents. We found that ERCC1-deficient lung cancer cells are tolerant to platinum-based chemotherapy, but ATR inhibition restored platinum sensitivity. This effect is dependent on ATR's replication fork protection and altered cell cycle checkpoints. Combined platinum and ATR inhibition also enhance response to immunotherapy in ERCC1-deficient tumors.
Meeting Abstract
Oncology
Yutuan Wu, Wei Hu, Nicholas Jennings, Yunjie Sun, Shannon Westin, Anil Sood
GYNECOLOGIC ONCOLOGY
(2022)
Review
Medicine, General & Internal
Lydia Choi, Kimberly Ku, Wei Chen, Awni D. Shahait, Steve Kim
Summary: This study found that at least one-quarter of patients with positive preoperative axillary needle biopsies may potentially only require sentinel lymph node biopsy instead of axillary lymph node dissection.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)